• Mashup Score: 0
    Trends in Sedentary Behavior Among US Adults - 38 minute(s) ago

    This study uses National Health and Nutrition Examination Survey data to examine changes in sedentary time among adults in the US from 2013 to 2023.

    Source: jamanetwork.com
    Categories: General Medicine News
    Tweet Tweets with this article
    • Profile photo of JAMA_current
      JAMA_current

      While sedentary behavior among US adults decreased from 2013 to March 2020, this trend stalled from 2021 to 2023. https://t.co/3NOsD4jVhn https://t.co/EWnQNcboDj

  • Mashup Score: 0
    First Blood Test for Alzheimer Biomarkers Receives FDA Clearance - 2 hour(s) ago

    This Medical News article discusses how the first FDA-cleared blood test for Alzheimer biomarkers should and shouldn’t be used.

    Source: jamanetwork.com
    Categories: General Medicine News
    Tweet Tweets with this article
    • Profile photo of JAMA_current
      JAMA_current

      The @US_FDA's clearance of a blood biomarker test for detecting amyloid plaques in the brain represents an advancement in #Alzheimer diagnosis and treatment, but it also raises concerns about potential misuse and overdiagnosis. https://t.co/Mt1aH1lkrD

  • Mashup Score: 0
    Current State of Reproductive Health Access - 4 hour(s) ago

    This Viewpoint examines US states’ attempts to address the consequences of abortion bans by clarifying them in various ways, a form of legislative interference that further limits access to reproductive health care.

    Source: jamanetwork.com
    Categories: General Medicine News
    Tweet Tweets with this article
    • Profile photo of JAMA_current
      JAMA_current

      Viewpoint: Legislative interference in medicine is harmful, and abortion bans should be repealed rather than clarified to ensure access to evidence-based reproductive health care. https://t.co/AkZ1X4jUMp https://t.co/XwJqGI31rU

  • Mashup Score: 0
    An Unusual Cause of Atrioventricular Block - 4 hour(s) ago

    This case report describes a man in his 60s who presented with a 3-day history of low-grade, intermittent fever, myalgia, and headache, along with episodes of blurred vision and recurrent syncope.

    Source: jamanetwork.com
    Categories: General Medicine News
    Tweet Tweets with this article
    • Profile photo of JAMAInternalMed
      JAMAInternalMed

      This case report describes a man in his 60s who presented with a 3-day history of low-grade, intermittent fever, myalgia, and headache, along with episodes of blurred vision and recurrent syncope. https://t.co/twuApR75J7 https://t.co/4EmfFYeFBK

  • Mashup Score: 0
    Next-In-Class vs Original Oncology Drugs - 5 hour(s) ago

    This cross-sectional study compares US Food and Drug Administration–approved anticancer “me-too,” or next-in-class, drugs with randomized clinical trial comparators of first-in-class drugs.

    Source: jamanetwork.com
    Categories: General Medicine News
    Tweet Tweets with this article
    • Profile photo of JAMAInternalMed
      JAMAInternalMed

      Among FDA anticancer drug approvals from 2009 to 2020, only 27 next-in-class drugs had direct randomized clinical trial comparisons with first-in-class drugs. https://t.co/qSkYe4E6Cm @Timothee_MD @ManniMD1 https://t.co/2UQzV8L2mE

  • Mashup Score: 0
    Tacrolimus or Mycophenolate Mofetil for Frequently Relapsing or Steroid-Dependent Nephrotic Syndrome - 5 hour(s) ago

    This randomized clinical trial conducted at 12 pediatric nephrology centers in China compares the effectiveness and safety of tacrolimus and mycophenolate mofetil in children with frequently relapsing nephrotic syndrome or steroid-dependent nephrotic syndrome.

    Source: jamanetwork.com
    Categories: General Medicine News
    Tweet Tweets with this article
    • Profile photo of JAMAPediatrics
      JAMAPediatrics

      Compared with mycophenolate mofetil, a 1-year course of tacrolimus therapy extended the period of relapse-free survival in children with frequently relapsing nephrotic syndrome or steroid-dependent nephrotic syndrome. https://t.co/qMNdmZmaYe https://t.co/Ne2JJWnrec

Load More